""

about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

FAculty directory

Back to alphabetical index

 

Scott Shore, PhD

Scott Shore, PhD

 

Associate Dean, Graduate Studies

Associate Professor, Fels Institute of Cancer Research
and Molecular Biology
Associate Professor, Biochemistry
Telephone:  215-707-3359

Fax:  215-707-2805

Email: sks@temple.edu

 

Dean's Staff

Department of Biochemistry

Fels Institute for Cancer Research and Molecular Biology

 

Educational Background:

 

Drexel University

 

Return to top

 

 

Research Interests:

 

Dr. Shore’s research interests has been on the mechanisms of cellular signaling. One area of signaling they have been studying is protein kinases. These enzymes are responsible for phosphorylation of specific amino acids, serine, threonine and tyrosine, in proteins. The lab has studied the Abl gene family members each of which encode a tyrosine kinase and the role of these proteins in cellular growth, differentiation and transformation. More recently his lab has been investigating a new phoshoprotein, Snp70, which has a very proline rich composition. His lab has found that this protein is a substrate for several kinases including a serine kinase, CKII, and tyrosine kinase, Src. The consequences of these post-translational modifications on function, stability and localization of the Snp70 protein is currently under investigation. In addition to phosphorylation another critical factor in cell signaling is the ability of individual proteins to interact and form larger functional complexes. One interacting domain that Dr. Shore’s lab has been studying is the SH3 domain. This modular domain binds proline-rich tracts in target proteins. The capture and release of proteins by the SH3 domain is a key step in the assembly and regulation of functional complexes. This is an area of investigation where the Snp70 protein has also provided a model, based upon its ability to bind distinct SH3 domain containing proteins.

 

                                Channel (1)

Return to top

 

 

PUBMED PUBLICATIONS :


Recent Medically Related Publications, Obtained from PubMed (Click on PubMed ID to view abstract)

16247467. Kumar RN, Shore SK, Dhanasekaran N, Neoplastic transformation by the gep oncogene, Galpha12, involves signaling by STAT3. Oncogene 25:6(899-906)2006 Feb 9

15180537. Tsygankov AY, Shore SK, Src: regulation, role in human carcinogenesis and pharmacological inhibitors. Curr Pharm Des 10:15(1745-56)2004

14766353. Russello SV, Shore SK, SRC in human carcinogenesis. Front Biosci 9:(139-44)2004 Jan 1

12957809. Russello SV, Shore SK, Src in human carcinogenesis. Front Biosci 8:(s1068-73)2003 Sep 1

12476303. Shore SK, Tantravahi RV, Reddy EP, Transforming pathways activated by the v-Abl tyrosine kinase. Oncogene 21:56(8568-76)2002 Dec 9

10639576. Gebauer G, Mirakhur B, Nguyen Q, Shore SK, Simpkins H, Dhanasekaran N, Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma 2008/C13 cells. Int J Oncol 16:2(321-5)2000 Feb

10391678. Feshchenko EA, Shore SK, Tsygankov AY, Tyrosine phosphorylation of C-Cbl facilitates adhesion and spreading while suppressing anchorage-independent growth of V-Abl-transformed NIH3T3 fibroblasts. Oncogene 18:25(3703-15)1999 Jun 24

9593722. Hsu TC, Shore SK, Seshsmma T, Bagasra O, Walsh PN, Molecular cloning of platelet factor XI, an alternative splicing product of the plasma factor XI gene. J Biol Chem 273:22(13787-93)1998 May 29

8943360. Zhu J, Shore SK, c-ABL tyrosine kinase activity is regulated by association with a novel SH3-domain-binding protein. Mol Cell Biol 16:12(7054-62)1996 Dec

8882949. Leopold LH, Shore SK, Reddy EP, Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia. Leuk Lymphoma 22:5-6(365-73)1996 Aug

8639797. Zhu J, Nabissa PM, Hoffman B, Liebermann DA, Shore SK, Activated abl oncogenes and apoptosis: differing responses of transformed myeloid progenitor cell lines. Blood 87:10(4368-75)1996 May 15

7556292. Urbain JL, Shore SK, Vekemans MC, Cosenza SC, DeRiel K, Patel GV, Charkes ND, Malmud LS, Reddy EP, Scintigraphic imaging of oncogenes with antisense probes: does it make sense? Eur J Nucl Med 22:6(499-504)1995 Jun

7718886. Leopold LH, Shore SK, Newkirk TA, Reddy RM, Reddy EP, Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood 85:8(2162-70)1995 Apr 15

8036026. Vara Prasad MV, Shore SK, Dhanasekaran N, Activated mutant of G alpha 13 induces Egr-1, c-fos, and transformation in NIH 3T3 cells. Oncogene 9:8(2425-9)1994 Aug

8106523. Shore SK, La Cava M, Yendapalli S, Reddy EP, Structural alterations in the carboxyl-terminal domain of the BCRABL gene product activate its fibroblastic transforming potential. J Biol Chem 269:7(5413-9)1994 Feb 18

7700900. Leopold LH, Shore SK, Newkirk T, Mangan K, Reddy EP, Ribozyme mediated therapy for chronic myelogenous leukemia. Prog Clin Biol Res 389:(175-82)1994

8414522. Shore SK, Nabissa PM, Reddy EP, Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity. Oncogene 8:11(3183-8)1993 Nov

Return to top